SAN FRANCISCO — After three decades working on cell and gene therapy, David DiGiusto has expertise that’s hard to find. So hard to find, in fact, that one cancer immunotherapy company stopped at nothing to try to hire him.
First, DiGiusto was told he could name his salary. Next, he was told he could name his desired equity stake. When those offers didn’t work, the chairman of the board tried to woo DiGiusto with a last-ditch deal: He’d buy DiGiusto a $10,000 Omega Speedmaster wristwatch — if only he’d join the company.